Navigation Links
Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy
Date:5/13/2009

DURHAM, N.C., May 13 /PRNewswire/ -- Addrenex Pharmaceuticals today expanded its pipeline of products aimed at adrenergic regulation with the signing of an agreement to license a new drug for the treatment of narcolepsy, a chronic and debilitating sleep disorder, as well as other neurologic and psychiatric conditions.

The agreement to license ADX-N05 gives Addrenex the worldwide rights (excluding East Asia) to develop, manufacture and commercialize the compound from SK Life Science Business Division, the drug-discovery and development division of SK Holdings Co. Ltd., one of the largest multinational companies based in South Korea.

"The partnership with SK Holdings embodies our commitment to seeking global alliances that further our goal of developing drugs for adrenergic regulation," said Steve Butts, Vice President of Commercial Operations for Addrenex Pharmaceuticals.

"We are pleased and excited to partner with an innovative, dynamic company such as SK Holdings, and we expect this to be the first of many global development partnerships for Addrenex," he added.

The licensing deal with SK Holdings provides Addrenex with its fourth drug candidate to enter clinical trials in three years. Each of Addrenex's drugs in development focuses on the treatment of medical conditions arising from an overactive or improperly regulated adrenergic system, a group of hormones and brain chemical messengers known as neurotransmitters. These hormones and neurotransmitters regulate diverse physiologic functions such as stress, pain, sleep and blood pressure.

Addrenex's lead products are Clonicel(R) for the treatment of attention-deficit hyperactivity disorder (ADHD) and Sympres(R) for the treatment of hypertension. The company also plans to develop drugs to treat menopausal flushing and potentially pain, insomnia and migraines, all of which are impacted by the adrenergic system.

'/>"/>

SOURCE Addrenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication
2. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
3. Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD
4. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
5. BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009
6. ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the Association for Research in Vision and Ophthalmology (ARVO) 2009 Annual Meeting
7. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
8. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
9. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
10. Transcept Pharmaceuticals to Report First Quarter 2009 Results
11. Oramed Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... SEATTLE, Wash. , Oct. 20, 2014 ... today that it will report its third quarter 2014 ... close of the U.S. financial markets. Following the announcement, ... conference call to discuss the results and provide a ... PDT). Access to the event can be obtained as ...
(Date:10/18/2014)... -- In a policy paper released today, ... lesbian, gay, bisexual and transgender (LGBT) civil rights ... Pre-Exposure Prophylaxis (PrEP). PrEP is any medical or ... of a disease or infection prior to exposure. ... combination currently approved for PrEP, which protects against ...
(Date:10/17/2014)... 2014  Hanger, Inc. (NYSE: HGR ) ... of operations for the quarter ended September 30, 2014, ... A conference call to discuss these results is scheduled ... 7, 2014. Those wishing to participate should call 1-877-662-6095. ... 2014 by dialing 1-855-859-2056 and referencing Conference ID # ...
Breaking Medicine Technology:CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 2HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 3
... The " Peripheral Vascular & ... (Balloons, EVAR Stent Grafts, IVC Filter, IVUS & Angiography ... Accessory Devices) Global Trends & Competitive Analysis " ... and opportunities in North America, Europe, Asia and Rest ...
... 2012 Earlier today the federal district court denied our ... of our license to ship controlled substances from our Lakeland, ... noticed our appeal of this decision to the U.S. Court ... contingency plans will be immediately activated, and we will make ...
Cached Medicine Technology:MarketsandMarkets: Global Peripheral Vascular & Interventional Cardiology Devices Market worth $37.9 Billion by 2016 2MarketsandMarkets: Global Peripheral Vascular & Interventional Cardiology Devices Market worth $37.9 Billion by 2016 3
(Date:10/20/2014)... (PRWEB) October 20, 2014 JZ Fitness, ... nutritional coaching, corporate wellness programming, authorship, international lecturing and ... excited to announce the release of the JZ Fitness ... many years of coaching thousands of individuals on nutrition, ... app that does not require calorie counting or cumbersome ...
(Date:10/20/2014)... 20, 2014 Rockynol Retirement Community ... on Oct. 14. The $11 million project will include ... a cooked-to-order kitchen with full-service restaurant style dining. , ... for first class Assisted Living apartments,” said Kara Hanzie, ... the highest quality of care and this investment is ...
(Date:10/20/2014)... Unveiled at the Sept. 18 board meeting, The Center for ... ROI on membership dues at 12.5. In other words, for ... value to member hospitals. The calculation used to determine member ... , “This is the first time we’ve actually been able ... is really sound,” said Bill Ryan , president and ...
(Date:10/19/2014)... Hastings and Hastings, a Phoenix personal injury law firm ... Phoenix area and across Arizona reports record demand in ... accidents. Statistics have indicated a steady increase in automobile ... Hastings and Hastings has seen a steady increase in ... been injured through no fault of their own that ...
(Date:10/19/2014)... been working in the garment industry for decades, LunaDress’ dress ... James, one of the company’s top designers, many ladies like ... that add beauty to them. Chiffon floor length outfits are ... new selection of 2014 long prom dresses. , As ... available in over 20 popular designs. The company intends to ...
Breaking Medicine News(10 mins):Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2
... depression, anxiety , , WEDNESDAY, Feb. 13 (HealthDay News) -- ... symptom relief are more likely to suffer cognitive shortfalls ... slowing down in the ability to process and remember ... rise in the rate of depression and anxiety. , ...
... year, millions of people are infected with noroviruses - commonly ... hours of vomiting and diarrhea. While most people recover in ... - in rare cases, especially among the elderly and infants ... of North Carolina School of Public Health have discovered that ...
... Judgment Against Widex and William Demant Companies, SALT ... SNCI ), a leading producer of advanced digital hearing ... number of press,releases related to a jury award of ... Group, Inc. v. Sonic Innovations,Inc., et al. While this ...
... The first genome-wide search for genes governing social behavior ... the amoebae Dictyostelium discoideum -- have more than 100 ... study by scientists at Rice University and Baylor College ... the journal Nature. It marks one of the first ...
... Senior Living Inc.,(NYSE: BKD ) announced today that ... 2007 financial results after the market closes on Wednesday,February ... to discuss,the results on February 28, 2008 at 10:00 ... (866) 845-7252 (from within the U.S.) or (706) 634-9069,(from ...
... (PHILADELPHIA) Scientists at The Wistar Institute have collaborated on ... to some of the deadliest cancers in humans. The culmination ... the development of new cancer therapies. , During much ... our cells exists in an inactive form, stored inside densely ...
Cached Medicine News:Health News:Marijuana Use Among MS Patients Raises Risk for Cognitive, Mood Problems 2Health News:Marijuana Use Among MS Patients Raises Risk for Cognitive, Mood Problems 3Health News:Vaccine for stomach flu may be possible, UNC research shows 2Health News:Sonic Innovations Not Included in Adverse Jury Verdict 2Health News:Microbial 'cheaters' help scientists ID 'social' genes 2Health News:Microbial 'cheaters' help scientists ID 'social' genes 3Health News:Brookdale Announces Fourth Quarter and Full Year 2007 Release and Earnings Call 2Health News:Scientists solve structure of gene regulator that plays key role in cancer 2Health News:Scientists solve structure of gene regulator that plays key role in cancer 3